Cargando…
Cohort profile: the Nigerian HIV geriatric cohort study
BACKGROUND: The Nigerian HIV Geriatric Cohort (NHGC) is a longitudinal cohort setup to learn how elderly people living with HIV (EPLHIV) in Nigeria fare, despite not being prioritized by the national treatment program, and to deepen knowledge for their differentiated care and achieve better outcomes...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690164/ https://www.ncbi.nlm.nih.gov/pubmed/33243227 http://dx.doi.org/10.1186/s12889-020-09833-9 |
_version_ | 1783614013247062016 |
---|---|
author | Dakum, Patrick Avong, Yohanna Kambai Odutola, Michael Kolawole Okuma, James Kayode, Gbenga Ayodele Nta, Iboro Ekpo Ndembi, Nicaise Mensah, Charles Khamofu, Hadiza Okonkwo, Prosper Okpanachi, John Oko Ezeanolue, Echezona |
author_facet | Dakum, Patrick Avong, Yohanna Kambai Odutola, Michael Kolawole Okuma, James Kayode, Gbenga Ayodele Nta, Iboro Ekpo Ndembi, Nicaise Mensah, Charles Khamofu, Hadiza Okonkwo, Prosper Okpanachi, John Oko Ezeanolue, Echezona |
author_sort | Dakum, Patrick |
collection | PubMed |
description | BACKGROUND: The Nigerian HIV Geriatric Cohort (NHGC) is a longitudinal cohort setup to learn how elderly people living with HIV (EPLHIV) in Nigeria fare, despite not being prioritized by the national treatment program, and to deepen knowledge for their differentiated care and achieve better outcomes. In this paper, we describe data collected on sociodemographic and clinical data from EPLHIV from the inception of Nigeria’s national HIV program to 2018. METHODS: Patient-level data spanning the period 2004 to 2018, obtained from comprehensive HIV treatment hospitals, that are supported by four major PEPFAR-implementing partners in Nigeria were used. These 4 entities collaborated as member organizations of the Nigeria Implementation Science Alliance. We defined elderly as those aged 50 years and above. From deidentified treatment records, demographic and clinical data of EPLHIV ≥50-year-old at ART initiation during the review period was extracted, merged into a single REDcap® database, and described using STATA 13. RESULTS: A total of 101,652 EPLHIV were analysed. Women accounted for 53,608 (53%), 51,037 (71%) of EPLHIV identified as married and 33,446 (51%) unemployed. Median age was 57.1 years (IQR 52–60 years) with a median duration on ART treatment of 4.1 years (IQR 1.7–7.1 years). ART profile showed that 97,586 (96%) were on 1st-line and 66,125 (65%) were on TDF-based regimens. Median body mass index (BMI) was 22.2 kg/m(2) (IQR 19.5–25.4 kg/m(2)) with 43,012 (55%), 15,081 (19%) and 6803 (9%) showing normal (BMI 18.5 – < 25 kg/m(2)), overweight (BMI 25 - < 30 kg/m(2)) and obese (BMI ≥30 kg/m(2)) ranges respectively. Prevalence of hypertension (systolic-BP > 140 mmHg or diastolic-BP > 90 mmHg) was 16,201 (21%). EPLHIV median CD4 count was 381 cells/μL (IQR 212–577 cells/μL) and 26,687 (82%) had a viral load result showing < 1000copies/ml within one year of their last visit. As for outcomes at their last visit, 62,821 (62%) were on active-in-treatment, 28,463 (28%) were lost-to-follow-up, 6912 (7%) died and 2456 (3%) had stopped or transferred out. Poor population death records and aversion to autopsies makes it almost impossible to estimate AIDS-related deaths. CONCLUSIONS: This cohort describes the clinical and non-clinical profile of EPLHIV in Nigeria. We are following up the cohort to design and implement intervention programs, develop prognostic models to achieve better care outcomes for EPLHIV. This cohort would provide vital information for stakeholders in HIV prevention, care and treatment to understand the characteristics of EPLHIV. |
format | Online Article Text |
id | pubmed-7690164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76901642020-11-30 Cohort profile: the Nigerian HIV geriatric cohort study Dakum, Patrick Avong, Yohanna Kambai Odutola, Michael Kolawole Okuma, James Kayode, Gbenga Ayodele Nta, Iboro Ekpo Ndembi, Nicaise Mensah, Charles Khamofu, Hadiza Okonkwo, Prosper Okpanachi, John Oko Ezeanolue, Echezona BMC Public Health Research Article BACKGROUND: The Nigerian HIV Geriatric Cohort (NHGC) is a longitudinal cohort setup to learn how elderly people living with HIV (EPLHIV) in Nigeria fare, despite not being prioritized by the national treatment program, and to deepen knowledge for their differentiated care and achieve better outcomes. In this paper, we describe data collected on sociodemographic and clinical data from EPLHIV from the inception of Nigeria’s national HIV program to 2018. METHODS: Patient-level data spanning the period 2004 to 2018, obtained from comprehensive HIV treatment hospitals, that are supported by four major PEPFAR-implementing partners in Nigeria were used. These 4 entities collaborated as member organizations of the Nigeria Implementation Science Alliance. We defined elderly as those aged 50 years and above. From deidentified treatment records, demographic and clinical data of EPLHIV ≥50-year-old at ART initiation during the review period was extracted, merged into a single REDcap® database, and described using STATA 13. RESULTS: A total of 101,652 EPLHIV were analysed. Women accounted for 53,608 (53%), 51,037 (71%) of EPLHIV identified as married and 33,446 (51%) unemployed. Median age was 57.1 years (IQR 52–60 years) with a median duration on ART treatment of 4.1 years (IQR 1.7–7.1 years). ART profile showed that 97,586 (96%) were on 1st-line and 66,125 (65%) were on TDF-based regimens. Median body mass index (BMI) was 22.2 kg/m(2) (IQR 19.5–25.4 kg/m(2)) with 43,012 (55%), 15,081 (19%) and 6803 (9%) showing normal (BMI 18.5 – < 25 kg/m(2)), overweight (BMI 25 - < 30 kg/m(2)) and obese (BMI ≥30 kg/m(2)) ranges respectively. Prevalence of hypertension (systolic-BP > 140 mmHg or diastolic-BP > 90 mmHg) was 16,201 (21%). EPLHIV median CD4 count was 381 cells/μL (IQR 212–577 cells/μL) and 26,687 (82%) had a viral load result showing < 1000copies/ml within one year of their last visit. As for outcomes at their last visit, 62,821 (62%) were on active-in-treatment, 28,463 (28%) were lost-to-follow-up, 6912 (7%) died and 2456 (3%) had stopped or transferred out. Poor population death records and aversion to autopsies makes it almost impossible to estimate AIDS-related deaths. CONCLUSIONS: This cohort describes the clinical and non-clinical profile of EPLHIV in Nigeria. We are following up the cohort to design and implement intervention programs, develop prognostic models to achieve better care outcomes for EPLHIV. This cohort would provide vital information for stakeholders in HIV prevention, care and treatment to understand the characteristics of EPLHIV. BioMed Central 2020-11-26 /pmc/articles/PMC7690164/ /pubmed/33243227 http://dx.doi.org/10.1186/s12889-020-09833-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Dakum, Patrick Avong, Yohanna Kambai Odutola, Michael Kolawole Okuma, James Kayode, Gbenga Ayodele Nta, Iboro Ekpo Ndembi, Nicaise Mensah, Charles Khamofu, Hadiza Okonkwo, Prosper Okpanachi, John Oko Ezeanolue, Echezona Cohort profile: the Nigerian HIV geriatric cohort study |
title | Cohort profile: the Nigerian HIV geriatric cohort study |
title_full | Cohort profile: the Nigerian HIV geriatric cohort study |
title_fullStr | Cohort profile: the Nigerian HIV geriatric cohort study |
title_full_unstemmed | Cohort profile: the Nigerian HIV geriatric cohort study |
title_short | Cohort profile: the Nigerian HIV geriatric cohort study |
title_sort | cohort profile: the nigerian hiv geriatric cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690164/ https://www.ncbi.nlm.nih.gov/pubmed/33243227 http://dx.doi.org/10.1186/s12889-020-09833-9 |
work_keys_str_mv | AT dakumpatrick cohortprofilethenigerianhivgeriatriccohortstudy AT avongyohannakambai cohortprofilethenigerianhivgeriatriccohortstudy AT odutolamichaelkolawole cohortprofilethenigerianhivgeriatriccohortstudy AT okumajames cohortprofilethenigerianhivgeriatriccohortstudy AT kayodegbengaayodele cohortprofilethenigerianhivgeriatriccohortstudy AT ntaiboroekpo cohortprofilethenigerianhivgeriatriccohortstudy AT ndembinicaise cohortprofilethenigerianhivgeriatriccohortstudy AT mensahcharles cohortprofilethenigerianhivgeriatriccohortstudy AT khamofuhadiza cohortprofilethenigerianhivgeriatriccohortstudy AT okonkwoprosper cohortprofilethenigerianhivgeriatriccohortstudy AT okpanachijohnoko cohortprofilethenigerianhivgeriatriccohortstudy AT ezeanolueechezona cohortprofilethenigerianhivgeriatriccohortstudy |